TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02440685
Drug: ASN002 RD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recommended dose of ASN002 from Part A
Study: NCT01923948
Drug: Placebo (for Pregabalin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oral dose of placebo given before surgery
Study: NCT02971306
Drug: standard medical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
Study: NCT02750319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02191852
Drug: Seresis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03597503
Drug: SPN-810
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dose
Study: NCT03597503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01451385
Drug: COV795
Approvals — FDA: no, EMA: no, PMDA: no
Description: COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)
Study: NCT00994149
Drug: Ora-plus
Normalized name: Ora-Plus Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, give every 8 hours.
Study: NCT01755325
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04227990
Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Study: NCT03984812
Drug: GSK3732394
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL
Study: NCT03984812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.
Study: NCT00370799
Drug: Caudal Epidural Injection with generic Celestone
Normalized name: Celestone Soluspan Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
Study: NCT00370799
Drug: Caudal Epidural Injection with Celestone
Normalized name: Celestone Soluspan Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
Study: NCT00370799
Drug: Caudal Epidural Injection with DepoMedrol
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
Study: NCT01738867
Drug: GSK1521498
Approvals — FDA: no, EMA: no, PMDA: no
Description: White HPMC capsule containing 10 mg of GSK1521498
Study: NCT01337518
Drug: EZN-4176
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
Study: NCT01738867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules to GSK1521498 or NTX
Study: NCT01847690
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cortef 5 mg tablets per os, 2x5 mg, one day, one time
Study: NCT04216706
Drug: tailored pharmaceutical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
Study: NCT01887184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline was given
Study: NCT01013090
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
Study: NCT01959412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
Study: NCT02338856
Drug: MB12066 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg bid (multiple dose, day 8)
Study: NCT02338856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg bid (multiple dose, day 8)
Study: NCT02624453
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
Study: NCT02094729
Drug: BAN2401 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
Study: NCT02094729
Drug: BAN2401 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
Study: NCT02094729
Drug: BAN2401 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
Study: NCT02094729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of placebo for 60 +/- 10 minutes.
Study: NCT04236219
Drug: ALLN-346
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
Study: NCT04236219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
Study: NCT02386449
Drug: sodium picosulfate, magnesium oxide and citric acid (Picoprep®)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01758913
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
Study: NCT02244229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00904904
Drug: Indomethacin ophthalmic solution
Normalized name: indomethacin Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
Study: NCT00904904
Drug: Ketorolac Ophthalmic Solution
Normalized name: ketorolac Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
Study: NCT04346329
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Group
Study: NCT00604630
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
Study: NCT01435486
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
Study: NCT01435486
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with an equivalent volume of normal saline.
Study: NCT01826448
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02588404
Drug: LHRH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients will be treated with LHRH agonist as standard therapy.
Study: NCT02612922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally twice daily for five days
Study: NCT00310596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9% saline at 0,6mL/kg at bolus rate
Study: NCT02671097
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
Study: NCT03325595
Drug: AEF0117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2, 0.6, 2, or 6mg of AEF0117
Study: NCT03325595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule placebo
Study: NCT00348673
Drug: UK-453,061
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
Study: NCT00348673
Drug: UK-453,061
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
Study: NCT01288001
Drug: Ostenil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Sodium Hyaluronate plus Mannitol injection
Study: NCT03910088
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Giving drug to relieve post-dural puncture headache
Study: NCT03910088
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: giving a drug to relieve post-dural puncture headache
Study: NCT03910088
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: giving a drug to relieve post-dural puncture headache
Study: NCT03910088
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: giving a drug to relieve post-dural puncture headache
Study: NCT02197234
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
Study: NCT02197234
Drug: AZD9291 tablet dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
Study: NCT02820857
Drug: Folfiri
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
Study: NCT01037907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or 5 g dose
Study: NCT01348386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04480658
Drug: Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe
Study: NCT00475189
Drug: loestrin 24/4 vs loestrin 1/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
Study: NCT00475189
Drug: loestrin 1/20
Normalized name: Loestrin 1/20 21 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
Study: NCT02114489
Drug: ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unique perfusion of ibandronate 3 mg IV
Study: NCT02114489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03058900
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly methotrexate in maximum tolerable dosis
Study: NCT01986374
Drug: HCG is introduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: must have good blastocysts
Study: NCT01584362
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of placebo
Study: NCT03145259
Drug: Diclofenac Epolamine Patch
Normalized name: Diclofenac Epolamine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: patch
Study: NCT03145259
Drug: diclofenac sodium solution
Normalized name: Diclofenac Sodium Solution
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: solution
Study: NCT02709330
Drug: Lunasin Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LunaRich X Capsules, Reliv Now, ProVantage
Study: NCT04523883
Drug: JS001
Normalized name: Janus Kinase Inhibitor JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 240mg every three week
Study: NCT00040469
Drug: Campath -1H
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00040469
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03685188
Drug: Sufentanil Citrate
Normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
Study: NCT00630435
Drug: Premarin®/MPA formulation A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00630435
Drug: Premarin®/MPA formulation B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00630435
Drug: Premarin®/MPA formulation C
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00630435
Drug: Premarin®/MPA currently marketed product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00163020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
Study: NCT00125320
Drug: RSD1235
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02683824
Drug: [18F]FP-R01-MG-F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: radioactive tracer
Study: NCT03804411
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide
Study: NCT01370265
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
Study: NCT03343626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline (0.9% NaCl) IM injection.
Study: NCT01779882
Drug: Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Study: NCT01779882
Drug: Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Study: NCT00615017
Drug: AZD9773 (CytoFab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusions
Study: NCT00673335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00602420
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral naproxen twice daily for 5-8 days.
Study: NCT01317225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
Study: NCT02501629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
Study: NCT02501629
Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
Study: NCT02501629
Drug: Oral Corticosteroid (OCS)
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
Study: NCT01268891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily; tablet; orally; 18 weeks
Study: NCT01268891
Drug: Azilect®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg daily; tablet; orally; 18 weeks
Study: NCT00657982
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg BID
Study: NCT02185066
Drug: CJ-30056 20/500mg (Test)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between.
Study: NCT01748838
Drug: CTX-4430
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
Study: NCT01748838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
Study: NCT01748838
Drug: CTX-4430
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
Study: NCT01748838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
Study: NCT04062591
Drug: Piroxicam group
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive 0.4 mg/kg piroxicam IM
Study: NCT04062591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline IM in the same dose of piroxicam
Study: NCT04005599
Drug: Remifentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous general anesthesia with propofol and remifentanil.
Study: NCT01416948
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
Study: NCT02210702
Drug: Ethinyl Estradiol 35mcg/Norethindrone 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02210702
Drug: Ethinyl Estradiol 20mcg/Norethindrone 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01480232
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Description: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
Study: NCT01480232
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule ingested orally daily for 12 weeks (84 days)
Study: NCT01480232
Drug: NicoDerm Patch (Active)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Study: NCT01480232
Drug: NRT Patch (Placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One NRT patch (Placebo) daily for first 6 weeks (42 days).
Study: NCT01843205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
Study: NCT02264015
Drug: Cilobradine, low, film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264015
Drug: Cilobradine, high, film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264015
Drug: Placebo, film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02661035
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg IV over 2 hours, day -6
Study: NCT01917552
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 1250 milligram (mg) / m² po bid (D1-14)
Study: NCT03557385
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
Study: NCT00857480
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.